Skip to main content
Caplight Logo









ImmuneSpec

ImmuneSpec

Private
NielHealthcare & Life Scienceshttps://immunespec.com/

Last Round

Seed

Mar 24, 2023

Total Funding Raised

$1.3M

Company Overview

ImmuneSpec is a biotechnology company that provides high-sensitivity immunopeptidomics analysis services for the development of vaccines, immunotherapeutics, and personalized medicine.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

immunopeptidomicsMHC-associated peptide proteomicsMAPPSpeptide screeningmass spectrometryimmunogenicity risk assessmentneoantigen discoverycontract research organizationCRObiotech servicesdrug de-riskingantigen presentationwet-lab servicesproteomicstarget validationprecision medicine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ImmuneSpec Comparables

Compare ImmuneSpec with similar companies based on industry and business-model similarity.

ImmuneSpec comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Pure MHC, LLC
78%
Bruker
76%
MS Bioworks
74%

ImmuneSpec Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMar 24, 2023

Key People

Founding team and executive leadership

Kurt Boonen

Chief Data Officer - Co-Founder

Founding Team

Elise Pepermans

CEO & co-founder

Founding Team

ImmuneSpec Investors

Notable investors and investment history

ImmuneSpec investors
InvestorRounds
HERAN PartnersSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 17, 2025

    Grew 33% QoQ from 9 to 12 employees.

  • Mar 24, 2023

    $1.3M round led by HERAN Partners

ImmuneSpec Filings

Explore SEC and related filing metadata, where available.

ImmuneSpec filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about ImmuneSpec's valuation, stock price, and market status.

Is ImmuneSpec a public or private company?

ImmuneSpec is a private company.

What is the current stock price of ImmuneSpec?

ImmuneSpec is a private company with no public stock price. No recent secondary market data is available.

How much is ImmuneSpec worth (valuation)?

Valuation information for ImmuneSpec is not publicly available.

Can I buy ImmuneSpec stock?

ImmuneSpec shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was ImmuneSpec's last funding round?

ImmuneSpec's most recent funding round was Seed on March 24, 2023.

Who are the main investors in ImmuneSpec?

Key investors in ImmuneSpec include HERAN Partners.

Will ImmuneSpec IPO soon?

No public IPO plans have been announced for ImmuneSpec.

How can I track ImmuneSpec secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor ImmuneSpec's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersNiel
Employee Range14
Year Founded2023
Last FundingMar 24, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?